Print Page      Close Window     


SEC Filings

OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document



OBE022: Potential first-in-class, oral and selective PGF2α receptor antagonist for preterm labor (PTL) OBE022 AT-A-GLANCE • Prostaglandin F2α (FP) receptor antagonist • Licensed from Merck Serono • IP Protection through 2037 • (COM 2037 with PTE) OBE022 INDICATIONS • Preterm labor (GA 24-34week) • Incidence: USA: 500,000; EU: 500,000; Asia: 6,900,000* • Economic burden for premature infants: ~$26 billion in the U.S. ($16.9 billion in infant medical care) COMPETITION No drug approved for acute use in the US; atosiban used in the EU;    Progesterone indicated for prevention in a sub-population in the US Phase 1 & DDI clinical trials completed • Oral administration • Favorable preclinical study outcomes * WHO ‘Born Too Soon: The Global Action Report on Preterm Birth’ 2012)